Terazosin compared prazosin

There was a tendency for patients to gain weight during Terazosin therapy. In placebo-controlled monotherapy trials, male and female patients receiving Terazosin gained a mean of 1.

Both differences were statistically significant. No significant changes were observed in high-density lipoprotein fraction and triglycerides compared to placebo. Analysis of clinical laboratory data following administration of Terazosin suggested the possibility of hemodilution based on decreases in hematocrit, hemoglobin, white blood cells, total protein and albumin.

Decreases in hematocrit and total protein have been observed with alpha-blockade and are attributed to hemodilution. Pharmacokinetics Terazosin hydrochloride administered as capsules is essentially completely absorbed in man.

Administration of capsules immediately after meals had a minimal effect on the extent of absorption. The time to reach peak plasma concentration however, was delayed by about 40 minutes.

Terazosin has been shown to undergo minimal hepatic first-pass metabolism and nearly all of the circulating dose is in the form of parent drug. The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours. In a study that evaluated the effect of age on Terazosin pharmacokinetics, the mean plasma half-lives were After oral administration the plasma clearance was decreased by The remainder is eliminated as metabolites.

The disposition of the compound in animals is qualitatively similar to that in man. Indications and Usage for Terazosin Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia BPH.

The long-term effects of Terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

Contraindications Terazosin capsules are contraindicated in patients known to be hypersensitive to Terazosin hydrochloride. A similar effect can be anticipated if therapy is interrupted for several days and then restarted.

Syncope has also been reported with other alpha-adrenergic blocking agents in association with rapid dosage increases or the introduction of another antihypertensive drug. Syncope is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe supraventricular tachycardia with heart rates of to beats per minute.

Additionally, the possibility of the contribution of hemodilution to the symptoms of postural hypotension should be considered.

To decrease the likelihood of syncope or excessive hypotension, treatment should always be initiated with a 1 mg dose of Terazosin capsules, given at bedtime. The 2 mg, 5 mg and 10 mg capsules are not indicated as initial therapy. Dosage should then be increased slowly, according to recommendations in the Dosage and Administration section and additional antihypertensive agents should be added with caution. The patient should be cautioned to avoid situations, such as driving or hazardous tasks, where injury could result should syncope occur during initiation of therapy.

In early investigational studies, where increasing single doses up to 7. Syncopal episodes occurred in 3 of the 14 subjects given Terazosin at doses of 2. These adverse effects all occurred within 90 minutes of dosing.

Syncope was not necessarily associated only with the first dose. Our experience is partly supported by some published trials [] although a systematic evaluation of the comparative efficacy and safety of various BPH medicines is still lacking. However, comparisons among many other agents were not fully discussed.

We noticed that this review was carried out based on a systematic search of electronic databases. A summary of the latest evidence regarding the comparative effects of various BPH medicines would be very useful for clinicians.

If possible, a secondary quantitative synthesis of trial data using pairwise meta-analysis or mixed-treatment comparison would provide clinicians with even stronger evidence. We believe most urologists would be applauded for that. No competing interests Reference 1. The management of lower urinary tract symptoms in men. A Multicentre, Prospective, Randomised Study. Int J Clin Pract ; A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.

Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia:

Tags: atorvastatin winthrop 20 mg best way give prevacid solutabs cpt code for boniva injection xenical 120mg india